Home › Trials › NCT07167251
Clinical trial Recruiting at 1 site Observational Ages 18 and up

Low-dose prednisolone for immune checkpoint inhibitor–related hepatitis

Official title: Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids - A Prospective Registry-based, Cohort Study

Run by University Hospital, Basel, Switzerland · NCT07167251 · Data updated 2026-11-12

This project will try low-dose prednisolone (0.5–1 mg/kg) to manage grade 2–3 immune-related hepatitis in adults receiving immune checkpoint inhibitors.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment63 (estimated)
SponsorUniversity Hospital, Basel, Switzerland
Academic / other
Drugs / interventionschemotherapy, prednisone, immunotherapy
Locations2 sites (Basel, Canton of Basel-City and 1 other locations)
StatusRecruiting
StartedAugust 25, 2025
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedSeptember 11, 2025
Trial IDNCT07167251 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult cancer patients on PD-1/PD-L1, CTLA-4, LAG-3, or combination immune checkpoint inhibitors who develop investigator‑judged grade 2–3 immune-related hepatitis and who have not already received high‑dose corticosteroids are the intended participants.

Probably not a fit

Patients presenting with grade 4 hepatitis, bilirubin >1.5×ULN, clinical suspicion of cholangitis, elevated INR beyond baseline, prior systemic treatment for immune-related hepatitis, or those who already received >0.5 mg/kg corticosteroids are unlikely to benefit from this low‑dose approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, registry-based cohort study enrolls adult cancer patients who develop grade 2–3 immune-related hepatitis while on PD-1, PD-L1, CTLA-4, LAG-3, or combination therapy. Participants receive a predefined low-dose prednisolone 'test dose' (0.5–1 mg/kg) with early clinical and laboratory reassessment to determine response and need for escalation. The study tracks control of hepatitis without higher-dose steroids or additional immunosuppression, steroid-related adverse events, and the ability to continue cancer immunotherapy. Data are collected across multiple European oncology centers using standardized management protocols.

Why it matters

Potential benefit: If successful, this approach could let many patients control hepatitis with lower steroid doses, reducing infections and other steroid harms while better preserving cancer treatment.

How similar studies have gone: Retrospective reports suggest lower corticosteroid doses can control some immune‑related hepatitis cases, but prospective evidence is limited and this targeted low‑dose strategy is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Cancer patients aged 18 years or older
2. Treatment with a programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) antibody, or a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or a combination of a PD-1 and CTLA-4 antibody, or a PD-1 and lymphocyte-activation gene 3 (LAG-3) antibody
3. Occurrence of immune-related hepatitis grade 2 to 3 (as per judgment of the investigator)
4. Ability of the patient to comply with the study procedures (management of immune-related hepatitis)

Exclusion Criteria:

1. Previous Immune-related hepatitis that required systemic therapy
2. Treatment for Immune-related hepatitis has already been initiated with high-dose corticosteroids (\>0.5 mg/kg body weight)
3. Immune-related hepatitis with bilirubin \> 1.5 ULN or clinical suspicion of cholangitis or elevated INR (beyond baseline)
4. Immune-related hepatitis with grade 4 at first presentation
5. Prior irAE treated with systemic immunosuppression
6. Simultaneous immune-related neurological toxicity or immune-related myocarditis (since these usually have to be treated with high doses of corticosteroids)

   a. Patients with other immune-related adverse events may be included according to the investigator's judgment
7. Known liver disease (e.g., autoimmune hepatitis, active hepatitis B, C or E, hemochromatosis, liver cirrhosis Child-Pugh Score B or C, primary biliary cholangitis, primary biliary cirrhosis, Morbus Wilson)

   a. Patients with liver metastasis are eligible
8. Patients receiving cancer treatment other than immune checkpoint inhibitors in parallel (e.g., tyrosine kinase inhibitors or chemotherapy).

   a. Patients who have received other cancer treatments in previous cycles are eligible, provided the treating physician does not assume any toxicity from the other medication.
9. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to occurrence of IR hepatitis. Stable corticosteroid doses of \< 10mg prednisone equivalent are allowed.

Where it's running

  • University Hospital Basel
    Basel, Canton of Basel-City, Switzerland     Recruiting
  • Royal Marsden Hospital
    London, United Kingdom     Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Immune-Related Adverse Events 8Immune-Mediated Hepatitis 5University Hospital, Basel, Switzerland 158
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.